References
- Germain DP. Fabry disease. Orphanet J Rare Dis 2010;5:30
- El-Abassi R, Singhal D, England JD. Fabry’s disease. J Neurol Sci 2014;344:5-19
- Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-54
- Scriver CR, ed. The Metabolic & Molecular Bases of Inherited Disease, Vol. 4. New York, Montreal: McGraw-Hill, 2001
- Bridges JFP, Hauber AB, Marshall DA, et al. Conjoint analysis applications in health – a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health 2011;14:403-13
- Devlin N, Shah K, Feng Y, et al. Valuing Health-Related Quality of Life: An EQ-5D-5L Value Set for England. Office of Health Economics, 2016
- Bansback N, Brazier J, Tsuchiya A, Anis A. Using a discrete choice experiment to estimate health state utility values. J Health Econ 2012;31:306-18
- Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727-36
- Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000370/WC500020547.pdf. Accessed in January 2016
- Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000369/WC500053612.pdf. Accessed in January 2016
- Beck M, Hughes D, Kampmann C, et al. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: a Fabry Outcome Survey analysis. Molecular Genetics and Metabolism Reports 2015;3:21-7
- Sirrs SM, Bichet DG, Casey R, et al. Outcomes of patients treated through the Canadian Fabry disease initiative. Mol Gen Metab 2014;111:499-506
- Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004059/WC500208434.pdf. Accessed in January 2016
- Lenders M, Stypmann J, Duning T, et al. Serum-mediated inhibition of enzyme replacement therapy in Fabry disease. J Am Soc Nephrol 2016;27:256-64
- World Bank. Available at: http://data.worldbank.org/indicator/SP.DYN.LE00.IN [Last accessed 25 February 2016]
- Office for National Statistics. Available at: https://www.ons.gov.uk [Last accessed 16 Feburary 2016]
- National Institute for Health and Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal. London: NICE, 2013